Montelucaste Teva (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes from binding. This inhibition reduces bronchoconstriction, mucus production, vascular leakage, and inflammatory cell recruitment, leading to improved airway patency and decreased allergic inflammation.

The appropriate dose of Montelucaste Teva is set by a qualified prescriber based on the patient’s age, weight, severity of disease, and response to therapy. No fixed dosing regimen is provided here; the clinician tailors the regimen to each individual.

Safety data for Montelucaste Teva in pregnancy are limited, and the product is not classified in a specific pregnancy category. Health‑care providers should weigh potential benefits against risks. Caution is also advised during breastfeeding, and a prescriber should evaluate infant exposure.

To request Montelucaste Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelucaste Teva belongs to the leukotriene‑modifier class, offering an oral alternative to inhaled corticosteroids or long‑acting bronchodilators. It is particularly useful for patients who prefer a tablet, have exercise‑induced symptoms, or need adjunct therapy, but it may be less potent than high‑dose inhaled steroids for severe persistent asthma.

Montelucaste Teva should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency.

Montelucaste Teva is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food, according to the prescriber’s instructions, and should be taken at the same time each day to maintain consistent blood levels.

Serious adverse events, although rare, include severe allergic reactions such as angioedema or anaphylaxis, neuropsychiatric effects like mood changes or suicidal thoughts, and hepatic injury. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelucaste Teva is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Caution is also advised for patients with uncontrolled liver disease, and it should be avoided in those who have experienced severe allergic reactions to leukotriene‑modifier drugs.